Purespring Positive About Prospects Despite Burst Biotech Bubble
UK Gene Therapy Moving Quickly Towards Clinic
Executive Summary
Some investors are shying away from early-stage gene therapy companies, but Richard Francis, CEO of kidney disease specialist Purespring, told Scrip that the pharmaceutical industry's appetite for the field has not waned and the best-equipped companies will flourish.
You may also be interested in...
Forcefield Therapeutics Launched With ‘Gamechanger’ Goal For Post-MI Therapy
The newly launched biotech has a novel platform for discovering protective tissue factors and turning them into therapies,with heart failure prevention its first target.
Novartis Sneaks Ahead Of Sanofi To Buy Gyroscope
The Swiss giant is paying up to $1.5bn upfront to get hold of Gyroscope's AAV2-based one-time investigational gene therapy for geographic atrophy, an advanced form of dry AMD that leads to irreversible vision loss.
Egetis Ends Takeover Talks To Focus On Emcitate
The Swedish firm has decided to pass on a bid from a proposed buyer which would have involved a healthy premium but “considerably undervalued” its long-term prospects.